Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
Status:
Recruiting
Trial end date:
2022-10-17
Target enrollment:
Participant gender:
Summary
This phase I/II trial identifies the side effects and best dose of pevonedistat when given
together with pembrolizumab in treating mismatch repair deficiency (dMMR)/high-frequency
microsatellite instability (MSI-H) solid tumor that has spread to other places in the body
(metastatic) or has spread to nearby tissue or lymph nodes (locally advanced) and cannot
removed by surgery (unresectable). Pevonedistat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Giving pevonedistat and
pembrolizumab may kill more tumor cells.